Application of the †5-2-1' screening criteria in advanced Parkinson's disease: Interim analysis of DUOGLOBE
- Aldred, J. 1
- Anca-Herschkovitsch, M. 2
- Antonini, A. 3
- Bajenaru, O. 4
- Bergmann, L. 5
- Bourgeois, P. 6
- Cubo, E. 7
- Davis, T.L. 8
- Iansek, R. 9
- Kovács, N. 10
- Kukreja, P. 5
- Onuk, K. 5
- Pontieri, F.E. 11
- Robieson, W. 5
- Siddiqui, M.S. 12
- Simu, M. 13
- Standaert, D.G. 14
- Ray Chaudhuri, K. 15
- 1 Selkirk Neurology and Inland Northwest Research, Spokane
-
2
Tel Aviv University
info
-
3
University of Padua
info
- 4 Department of Neurology, University of Medicine and Pharmacy Carol Davila, Bulevardul Eroii Sanitari 8
- 5 AbbVie Inc.
- 6 Department of Neurology Az Groeninge
-
7
Complejo Asistencial Universitario de Burgos
info
-
8
Vanderbilt University Medical Center
info
- 9 Kingston Centre, Monash Health
- 10 Department of Neurology, University of Pecs
-
11
Università de Roma La Sapienza
info
- 12 Department of Neurology, Wake Forest School of Medicine
- 13 Department of Neurology, Victor Babes University of Medicine and Pharmacy
-
14
University of Alabama at Birmingham
info
- 15 Parkinson Foundation International Centre of Excellence, King's College and King's College Hospital
Journal:
Neurodegenerative Disease Management
ISSN: 1758-2032
Year of publication: 2020
Volume: 10
Issue: 5
Pages: 309-323
Type: Article
DOI:
10.2217/NMT-2020-0021
PMID:
32873195
SCOPUS:
2-s2.0-85096241833
GOOGLE SCHOLAR
lock_openOpen access editor
Data source: Scopus